Skip to content
OpenCapital
Get started

Krystal Biotech, Inc. KRYS Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

Incyte logo
IncyteINCY
——
Viatris logo
ViatrisVTRS
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$10.26B+45.4%
Enterprise value$9.77B+44.2%
P/E45.6×-11.3×
P/S24.6×+3.4×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0×0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Krystal Biotech, Inc.'s share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Krystal Biotech, Inc.'s share-based payment award options outstanding - number?
Krystal Biotech, Inc. (KRYS) reported share-based payment award options outstanding - number of 2.1M in Q1 2026.
How has Krystal Biotech, Inc.'s share-based payment award options outstanding - number changed year-over-year?
Krystal Biotech, Inc.'s share-based payment award options outstanding - number decreased by 6.9% year-over-year, from 2.3M to 2.1M.
What is the long-term trend for Krystal Biotech, Inc.'s share-based payment award options outstanding - number?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s share-based payment award options outstanding - number has grown at a 18.9% compound annual growth rate (CAGR), from 853.6K to 2M.